Introduction to In Vivo Testing

Bioavailability Study Definition:

Bioavailability studies involve the assessment of the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For oral dosage forms like tablets, this typically involves measuring drug concentration in blood or plasma over time following administration.

Approaches to In Vivo Testing:

Animal Studies

In vivo testing of tablet formulations involves studies in animals prior to studies in humans. Animal studies provide preliminary data on safety, pharmacokinetics, and bioavailability before human trials.

Direct Human Studies

In the case of generic formulations, tablet formulations may be studied directly in humans. This approach is based on the reference product's established safety profile and the need to demonstrate bioequivalence.

Multiple Formulation Testing:

When in vivo studies in humans are undertaken, it may be desirable or even essential to conduct such studies with more than one formulation. This is particularly true if a goal of product design is product optimization and a primary objective is to maximize bioavailability or response versus time profile.

Bioavailability Study Design Strategy

Optimal Study Design:

A bioavailability study should eventually be run comparing three distinct formulations:

Optimized Formulation

The formulation with the best predicted performance based on preliminary studies

→

Slowest Dissolution

A formulation (within the excipient ranges) predicted to have the slowest dissolution

→

Fastest Dissolution

A formulation (within the excipient ranges) predicted to have the fastest dissolution

Rationale for Three-Formulation Design:

  1. Range Testing: Evaluates the entire spectrum of possible dissolution rates within the defined excipient ranges
  2. IVIVC Establishment: Allows correlation between in vitro dissolution and in vivo bioavailability parameters
  3. Specification Setting: Provides data to establish meaningful dissolution specifications
  4. Robustness Assessment: Tests the formulation's performance at the extremes of the design space

Critical Objective:

The primary objective of testing formulations with different dissolution rates is to determine if they are bioequivalent. If bioequivalence is demonstrated across the dissolution range, the excipient ranges are considered valid from an in vivo performance perspective.

In Vitro-In Vivo Correlation (IVIVC)

IVIVC Definition:

In Vitro-In Vivo Correlation (IVIVC) is a predictive mathematical model describing the relationship between an in vitro property of a dosage form (usually the rate or extent of drug dissolution or release) and a relevant in vivo response (e.g., plasma drug concentration or amount of drug absorbed).

Purpose of Establishing IVIVC:

Specification Setting

The bioavailability study results can be used to establish a correlation between the in vitro dissolution test and the in vivo bioavailability parameters. This correlation forms the basis for setting meaningful dissolution specifications.

Bioequivalence Prediction

IVIVC allows prediction of in vivo performance based on in vitro dissolution data, reducing the need for extensive human studies for minor formulation changes.

Quality Control

Dissolution testing becomes a more meaningful quality control tool when correlated with in vivo performance, ensuring batch-to-batch consistency in bioavailability.

Levels of IVIVC:

Level Description Application
Level A Point-to-point correlation between in vitro dissolution and in vivo input rate Highest level of correlation; most useful for regulatory purposes
Level B Comparison of mean in vitro dissolution time to mean in vivo residence time Uses statistical moment analysis
Level C Single point correlation between dissolution parameter and pharmacokinetic parameter Least useful for predicting entire time course
Multiple Level C Correlation at several time points of dissolution with pharmacokinetic parameters More useful than single point Level C correlation

Bioequivalence Assessment

Bioequivalence Criteria:

Two formulations are considered bioequivalent if their rate and extent of absorption are not statistically significantly different when administered at the same molar dose under similar experimental conditions. Typically, bioequivalence is declared if the 90% confidence interval for the ratio of the geometric means of the test to reference product falls within 80-125% for AUC (extent) and Cmax (rate).

Outcome Scenarios:

Scenario 1: Bioequivalence Demonstrated

If the three formulations (optimal, slow, and fast-dissolving) turn out to be bioequivalent, the excipient ranges are valid from the in vivo performance viewpoint.

Implication: The formulation design space is robust, and dissolution specifications can be set based on the tested range.

Scenario 2: Bioequivalence Not Demonstrated

If the three formulations are not bioequivalent, then the excipient ranges should be tightened using the in vitro/in vivo correlation.

Implication: The formulation design space needs refinement, and tighter control of excipient ranges is required.

Regulatory Response to Non-Bioequivalence:

  1. Range Tightening: Excipient ranges should be tightened using the established IVIVC to ensure bioequivalence
  2. Specification Revision: The specifications for the dissolution of the tablet should be set based on this correlation
  3. Reformulation Consideration: May require reformulation to achieve desired bioavailability within acceptable excipient ranges
  4. Additional Studies: May necessitate additional bioavailability studies to confirm performance of revised formulation

Practical Implementation of Bioavailability Studies

Study Design Elements:

Element Description Considerations
Study Population Healthy volunteers (usually 18-55 years) with appropriate inclusion/exclusion criteria Size typically 12-36 subjects based on variability and regulatory requirements
Study Design Randomized, crossover design with adequate washout period Balanced for sequence effects; single or multiple dose depending on objective
Dosing Conditions Fasting or fed conditions as specified by regulatory guidelines Consistent administration conditions across all study periods
Sampling Schedule Blood/plasma samples collected at predetermined time points Adequate sampling to characterize absorption, distribution, and elimination phases
Analytical Methods Validated bioanalytical methods for drug quantification Must meet criteria for specificity, sensitivity, accuracy, and precision
Statistical Analysis ANOVA for pharmacokinetic parameters with 90% confidence intervals Log-transformed data for AUC and Cmax; bioequivalence acceptance criteria 80-125%

Key Pharmacokinetic Parameters Measured:

AUC0-t & AUC0-∞

Area Under the Curve from time zero to last measurable concentration (AUC0-t) and extrapolated to infinity (AUC0-∞). Measures extent of absorption.

Cmax

Maximum plasma concentration. Measures rate of absorption.

Tmax

Time to reach maximum plasma concentration. Additional indicator of absorption rate.

t½

Elimination half-life. Determines dosing interval and steady-state concentrations.

Integration with Formulation Development

Systematic Approach:

Bioavailability studies should not be viewed as isolated tests but as integral components of the formulation development process, providing critical feedback for formulation optimization and quality control strategy development.

Formulation Development Workflow:

  1. Preformulation Studies: Characterize drug substance properties affecting bioavailability (solubility, permeability, stability)
  2. Formulation Design: Develop initial formulations based on drug properties and target product profile
  3. In Vitro Screening: Evaluate dissolution characteristics and physical properties of prototype formulations
  4. Animal Studies: Conduct preliminary pharmacokinetic studies in animals (if applicable)
  5. Human Bioavailability Studies: Test optimized, slow-dissolving, and fast-dissolving formulations in humans
  6. IVIVC Development: Establish correlation between in vitro dissolution and in vivo performance
  7. Specification Setting: Define dissolution specifications based on IVIVC and bioequivalence data
  8. Control Strategy: Implement quality control measures to ensure consistent bioavailability

Strategic Considerations:

The selection of which formulations to test in bioavailability studies should be guided by the principles of Quality by Design (QbD). Testing formulations at the extremes of the design space (slowest and fastest dissolving) provides maximum information about the robustness of the formulation and the validity of the excipient ranges.

Regulatory Implications:

Bioavailability Data in Regulatory Submissions:

  • New Drug Applications (NDAs): Comprehensive bioavailability data supporting formulation design and establishing therapeutic window
  • Abbreviated New Drug Applications (ANDAs): Bioequivalence data comparing generic formulation to reference listed drug (RLD)
  • Post-approval Changes: IVIVC can support certain post-approval changes without additional bioavailability studies
  • Scale-up and Post-approval Changes (SUPAC): Bioavailability data may be required for significant manufacturing changes

Final Consideration:

The ultimate goal of bioavailability studies in tablet formulation is to ensure that the final product delivers the drug in a manner that is both therapeutically effective and consistently reproducible. By testing formulations across the designed dissolution range and establishing meaningful IVIVC, formulators can create robust products with well-understood performance characteristics that meet both patient needs and regulatory requirements.